Pembrolizumab-associated chronic rhinosinusitis: A new endotype and management considerations

Taylor C Standiford; Neil N Patel; Amritpal Singh; Grant Gochman; Tara Jamie Wu; Adil I Daud; Andrew N Goldberg

doi:10.1002/alr.23213

Pembrolizumab-associated chronic rhinosinusitis: A new endotype and management considerations

Int Forum Allergy Rhinol. 2023 Dec;13(12):2248-2251. doi: 10.1002/alr.23213. Epub 2023 Jul 5.

Authors

Taylor C Standiford¹, Neil N Patel¹, Amritpal Singh¹, Grant Gochman¹, Tara Jamie Wu², Adil I Daud³, Andrew N Goldberg¹

Affiliations

¹ Division of Rhinology and Sinus Surgery, Department of Otolaryngology-Head & Neck Surgery, University of California, San Francisco, California, USA.
² Department of Otolaryngology-Head & Neck Surgery, University of California, Los Angeles, California, USA.
³ Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California, USA.

PMID: 37317899
DOI: 10.1002/alr.23213

Abstract

Patients treated with pembrolizumab experience an increase in paranasal sinus inflammation Use of topical triamcinolone in carboxymethylcellulose is a treatment option for such patients.

Keywords: chronic rhinosinusitis; immunotherapy; sinonasal inflammation.

MeSH terms

Chronic Disease
Humans
Paranasal Sinuses*
Rhinitis* / drug therapy
Sinusitis* / drug therapy

Substances

pembrolizumab